Post-ISCHEMIA Trial Era: Reconsideration of the Role of Nuclear Cardiology in Patients with Chronic Coronary Artery Disease

Overview

Journal Ann Nucl Cardiol

Date 2022 Dec 21

PMID 36540172

Authors

Keisuke Kiso

Atsuro Masuda

Kentaro Takanami

Tomohiro Kaneta

Kei Takase

Affiliations

Soon will be listed here.

Abstract

The International Study of Comparative Health Effectiveness with Medical and Invasive Approaches (ISCHEMIA) trial has had a great impact on the management of chronic coronary artery disease (CAD). One of the implications of this trial is the importance of close patient follow-up. To improve patient prognosis, evaluation of the residual extent of ischemia after treatment may be important because several studies have shown a close relationship between residual ischemia and cardiac events. For this assessment, myocardial perfusion single-photon emission computed tomography (MPS) has been utilized and is almost the only modality. Among the participants in the ISCHEMIA trial, more than 10% were excluded due to the absence of obstructive CAD. The pathophysiology of ischemia without non-obstructive coronary artery disease (INOCA) is gaining recognition; however, diagnosis is difficult, except for the assessment of myocardial flow reserve (MFR). Myocardial perfusion positron emission tomography (PET) is the most common modality for noninvasive evaluation of MFR; however, its availability in Japan is limited. For a breakthrough in this situation, a novel gamma camera with a cadmium zinc telluride (CZT) semiconductor might be one of the solutions that enables the evaluation of MFR with a commercially available perfusion tracer, similar to PET. Another solution is a novel PET tracer with a longer half-life. Clinical trials with F labeled perfusion agents have been initiated in Japan, and in a few years, delivery of this perfusion tracer will result in more frequent and easier assessment of MFR.

References

Ben-Haim S, Murthy V, Breault C, Allie R, Sitek A, Roth N . Quantification of Myocardial Perfusion Reserve Using Dynamic SPECT Imaging in Humans: A Feasibility Study. J Nucl Med. 2013; 54(6):873-9. PMC: 3951831. DOI: 10.2967/jnumed.112.109652. View

Maddahi J, Lazewatsky J, Udelson J, Berman D, Beanlands R, Heller G . Phase-III Clinical Trial of Fluorine-18 Flurpiridaz Positron Emission Tomography for Evaluation of Coronary Artery Disease. J Am Coll Cardiol. 2020; 76(4):391-401. DOI: 10.1016/j.jacc.2020.05.063. View

Kawano M, Tsuchiya J, Bae H, Kimura K, Yokoyama K, Takahashi M . Phase I clinical study of NMB58, a novel positron emission tomography (PET)-myocardial perfusion imaging tracer, conducted to evaluate its safety and pharmacokinetics in Japanese healthy adult males. Ann Nucl Med. 2021; 35(5):580-588. DOI: 10.1007/s12149-021-01601-y. View

Shiraishi S, Sakamoto F, Tsuda N, Yoshida M, Tomiguchi S, Utsunomiya D . Prediction of left main or 3-vessel disease using myocardial perfusion reserve on dynamic thallium-201 single-photon emission computed tomography with a semiconductor gamma camera. Circ J. 2015; 79(3):623-31. DOI: 10.1253/circj.CJ-14-0932. View

Nakano S, Kohsaka S, Chikamori T, Fukushima K, Kobayashi Y, Kozuma K . JCS 2022 Guideline Focused Update on Diagnosis and Treatment in Patients With Stable Coronary Artery Disease. Circ J. 2022; 86(5):882-915. DOI: 10.1253/circj.CJ-21-1041. View

Murthy V, Naya M, Taqueti V, Foster C, Gaber M, Hainer J . Effects of sex on coronary microvascular dysfunction and cardiac outcomes. Circulation. 2014; 129(24):2518-27. PMC: 4076200. DOI: 10.1161/CIRCULATIONAHA.113.008507. View

Murthy V, Naya M, Foster C, Hainer J, Gaber M, Di Carli G . Improved cardiac risk assessment with noninvasive measures of coronary flow reserve. Circulation. 2011; 124(20):2215-24. PMC: 3495106. DOI: 10.1161/CIRCULATIONAHA.111.050427. View

Kunadian V, Chieffo A, Camici P, Berry C, Escaned J, Maas A . An EAPCI Expert Consensus Document on Ischaemia with Non-Obstructive Coronary Arteries in Collaboration with European Society of Cardiology Working Group on Coronary Pathophysiology & Microcirculation Endorsed by Coronary Vasomotor Disorders.... Eur Heart J. 2020; 41(37):3504-3520. PMC: 7577516. DOI: 10.1093/eurheartj/ehaa503. View

Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C . 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2019; 41(3):407-477. DOI: 10.1093/eurheartj/ehz425. View

10.

Maddahi J, Packard R . Cardiac PET perfusion tracers: current status and future directions. Semin Nucl Med. 2014; 44(5):333-43. PMC: 4333146. DOI: 10.1053/j.semnuclmed.2014.06.011. View

11.

Shaw L, Berman D, Maron D, Mancini G, Hayes S, Hartigan P . Optimal medical therapy with or without percutaneous coronary intervention to reduce ischemic burden: results from the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial nuclear substudy. Circulation. 2008; 117(10):1283-91. DOI: 10.1161/CIRCULATIONAHA.107.743963. View

12.

Taqueti V, Di Carli M . Coronary Microvascular Disease Pathogenic Mechanisms and Therapeutic Options: JACC State-of-the-Art Review. J Am Coll Cardiol. 2018; 72(21):2625-2641. PMC: 6296779. DOI: 10.1016/j.jacc.2018.09.042. View

13.

Maron D, Hochman J, Reynolds H, Bangalore S, OBrien S, Boden W . Initial Invasive or Conservative Strategy for Stable Coronary Disease. N Engl J Med. 2020; 382(15):1395-1407. PMC: 7263833. DOI: 10.1056/NEJMoa1915922. View

14.

Agostini D, Roule V, Nganoa C, Roth N, Baavour R, Parienti J . First validation of myocardial flow reserve assessed by dynamic Tc-sestamibi CZT-SPECT camera: head to head comparison with O-water PET and fractional flow reserve in patients with suspected coronary artery disease. The WATERDAY study. Eur J Nucl Med Mol Imaging. 2018; 45(7):1079-1090. PMC: 5953996. DOI: 10.1007/s00259-018-3958-7. View

15.

Nanasato M, Matsumoto N, Nakajima K, Chikamori T, Moroi M, Takehana K . Prognostic impact of reducing myocardial ischemia identified using ECG-gated myocardial perfusion SPECT in Japanese patients with coronary artery disease: J-ACCESS 4 study. Int J Cardiol. 2018; 267:202-207. DOI: 10.1016/j.ijcard.2018.05.090. View

16.

Boden W, ORourke R, Teo K, Hartigan P, Maron D, Kostuk W . Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med. 2007; 356(15):1503-16. DOI: 10.1056/NEJMoa070829. View

17.

Taqueti V, Hachamovitch R, Murthy V, Naya M, Foster C, Hainer J . Global coronary flow reserve is associated with adverse cardiovascular events independently of luminal angiographic severity and modifies the effect of early revascularization. Circulation. 2014; 131(1):19-27. PMC: 4286486. DOI: 10.1161/CIRCULATIONAHA.114.011939. View

18.

Otaki Y, Manabe O, Miller R, Manrique A, Nganoa C, Roth N . Quantification of myocardial blood flow by CZT-SPECT with motion correction and comparison with O-water PET. J Nucl Cardiol. 2019; 28(4):1477-1486. PMC: 7042031. DOI: 10.1007/s12350-019-01854-1. View